参考文献/References:
[1] Jia G,Hill MA ,Sowers JR. Diabetic cardiomyopathy:an update of mechanisms contributing to this clinical entity[J]. Circ Res,2018,122(4):624-638.
[2] Dandamudi S,Slusser J,Mahoney DW,et al. The prevalence of diabetic cardiomyopathy:a population-based study in Olmsted County,Minnesota[J]. J Card Fail,2014,20(5):304-309.
[3] Boudina S,Abel ED. Diabetic cardiomyopathy revisited[J]. Circulation,2007 ,115(25):3213-3223.
[4] Li J,Su S ,Zong X. Analysis of the association between adiponectin,adiponectin receptor 1 and diabetic cardiomyopathy[J]. Exp Ther Med,2014,7(4):1023-1027.
[5] Shaver A,Nichols A,Thompson E,et al. Role of serum biomarkers in early detection of diabetic cardiomyopathy in the West Virginian population[J]. Int J Med Sci,2016 ,13(3):161-168.
[6] 苏仕月,李结华,宗晓娜. 脂联素及脂联素受体1的表达与糖尿病心肌病的关系[J]. 中国循证心血管医学杂志,2014,6(5):562-564.
[7] Shibata R,Ouchi N,Ito M,et al.Adiponectin-mediated modulation of hypertrophic signals in the heart[J]. Nat Med,2004 ,10(12):1384-1389.
[8] Gandhi PU,Gaggin HK,Sheftel AD,et al. Prognostic usefulness of insulin-like growth factor-binding protein 7 in heart failure with reduced ejection fraction:a novel biomarker of myocardial diastolic function?[J]. Am J Cardiol,2014,114(10):1543-1549.
[9] Chen WJY,Greulich S,van der Meer RW,et al. Activin A is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes[J] . Cardiovasc Diabetol,2013 ,12:150.
[10] Blumensatt M,Greulich S,Herzfeld de Wiza D,et al. Activin A impairs insulin action in cardiomyocytes via up-regulation of miR-143[J]. Cardiovasc Re s,2013,100(2):201-210.
[11] Liu Z,Zhao N,Zhu H,et al. Circulating interleukin-1β promotes endoplasmic reticulum stress-induced myocytes apoptosis in diabetic cardiomyopathy via interleukin-1 receptor-associated kinase-2[J]. Cardiovasc Diabetol,2015,14:125.
[12] Dominguez-Rodriguez A,Abreu-Gonzalez P,Avanzas P. Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus[J]. Am J Cardiol,2014,114(6):890-894.
[13] 刘欢,李艳. 生长分化因子-15在常见心血管疾病中的研究进展[J]. 微循环学杂志, 2017,27(4):68-71.
[14] 孙立娟,齐东旭. 糖尿病心肌病的早期临床诊断[J]. 中国实验诊断学,2010,14(10): 1647-1649.
[15] Korkmaz-Ic?z S,Lehner A,Li S,et al. Left ventricular pressure-volume measurements and myocardial gene expression profile in type-2 diabetic Goto-Kakizaki rats[J]. Am J Physiol Heart Circ Physiol,2016,311(4):H958-H971.
[16] Russell N, Higgins M, Amaruso M,et al. Troponin T and pro-B-type natriuretic Peptide in fetuses of type 1 diabetic mothers [J]. Diabetes Care,2009, 32(11): 2050-2055.
[17] Hoffmann U,Espeter F,Wei? C,et al.Ischemic biomarker heart-type fatty acid binding protein(hFABP) in acute heart failure - d iagnostic and prognostic insights compared to NT-proBNP and troponin I[J]. BMC Cardiovasc Disord,2015 ,15:50.
[18] Akbal E,?zbek M,Güne? F,et al. Serum heart type fatty acid binding protein levels in metabolic syndrome[J]. Endocrine,2009 ,36(3):433-437.
[19] Shearer J,Fueger PT,Wang Z,et al. Metabolic implications of reduced heart-type fatty acid binding protein in insulin resistant cardiac muscle[J]. Biochim Biophys Acta,2008,1782(10):586-592.
[20] Stejskal D,Ruzicka V. Cardiotrophin-1. Review[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2008,152(1):9-19.
[21] Gamella-Pozuelo L,Fuentes-Calvo I,Gómez-Marcos MA,et al. Plasma cardiotrophin-1 as a marker of hypertension and diabetes-induced target organ damage and cardiovascular risk[J]. Medicine(Baltimore),2015,94(30):e1218.
[22] Martínez-Martínez E,Brugnolaro C,Ibarrola J,et al. CT-1(cardiotrophin-1)-Gal-3 (galectin-3) axis in cardiac fibrosis and inflammation[J]. Hypertension,2019,73(3):602-611.
[23] Sarrazy V,Koehler A,Chow ML,et al. Integrins αvβ5 and αvβ3 promote latent TGF-β1 activation by human cardiac fibroblast contraction[J]. Cardiovasc Res,2014,102(3):407-417.
[24] Tan SM,Zhang Y,Wang B,et al. FT23,an orally active antifibrotic compound,attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy[J]. Clin Exp Pharmacol Physiol,2012,39(8):650-656.
[25] Iaccarino G,Barbato E,Cipolletta E,et al. Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure[J]. Eur Heart J,2005,26(17):1752-1758.
[26] Lai S,Fu X,Yang S,et al. G protein-coupled receptor kinase-2:a potential biomarker for early diabetic cardiomyopathy[J]. J Diabetes,2020 ,12(3):247-258.
[27] Chen Y,Xu F,Zhang L,et al. GRK2/β-arrestin mediates arginine vasopressin-induced cardiac fibroblast proliferation[J]. Clin Exp Pharmacol Physiol,2017,44(2):285-293.
[28] Ihm SH,Youn HJ,Shin DI,et al. Serum carboxy-terminal propeptide of type I procollagen(PIP) is a marker of diastolic dysfunction in patients with early type 2 diabetes mellitus[J]. Int J Cardiol,2007,122(3):e36-e38.
[29] Quilliot D,Alla F,B?hme P,et al. Myocardial collagen turnover in normotensive obese patients:relation to insulin resistance[J]. Int J Obes (Lond),2005,29(11):1321-1328.
[30] Visse R,Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases:structure,function,and biochemistry[J]. Circ Res,2003,92(8):827-839.
[31] van Linthout S,Seeland U,Riad A,et al. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy[J]. Basic Res Cardiol,2008,103(4):319-327.
[32] Ban CR,Twigg SM,Franjic B,et al. Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic dysfunction[J]. Diabetes Res Clin Pract,2010 ,87(3):335-341.
[33] Yao S. MicroRNA biogenesis and their functions in regulating stem cell potency and differentiation[J]. Biol Proced Online,2016,18:8.
[34] Tao L,Huang X,Xu M,et al. Value of circulating miRNA-21 in the diagnosis of subclinical diabetic cardiomyopathy[J]. Mol Cell Endocrinol,2020 ,518:110944.
[35] Wen P,Song D,Ye H,et al. Circulating MiR-133a as a biomarker predicts cardiac hypertrophy in chronic hemodialysis patients[J]. PLoS One,2014,9(10):e103079.
[36] Chen S,Puthanveetil P,Feng B,et al. Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes[J]. J Cell Mol Med,2014,18(3):415-421.
[37] Copier CU,León L,Fernández M,et al. Circulating miR-19b and miR-181b are potential biomarkers for diabetic cardiomyopathy[J]. Sci Rep,2017,7(1):13514.
相似文献/References:
[1]王静娜,侯瑞田,史亦男,等.糖尿病心肌病发病机制及病理改变研究进展[J].心血管病学进展,2016,(4):412.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.022]
WANG Jingna,HOU Ruitian,SHI Yinan,et al.Research Progress on Pathogenesis and Pathological Changes
of Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(5):412.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.022]
[2]杨沫,姜文锡.线粒体功能异常在糖尿病心肌病发病机制中的作用[J].心血管病学进展,2015,(6):731.[doi:10.3969/j.issn.1004-3934.2015.06.019]
YANG Mo,JIANG Wenxi.Mitochondrial Dysfunction of Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2015,(5):731.[doi:10.3969/j.issn.1004-3934.2015.06.019]
[3]朱月红,戴启明.糖尿病心肌病的内质网病变机制及干预[J].心血管病学进展,2015,(6):738.[doi:10.3969/j.issn.1004-3934.2015.06.021]
ZHU Yuehong,DAI Qiming.Advance of Mechanism and Intervention of Endoplasmic Reticulum in
Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2015,(5):738.[doi:10.3969/j.issn.1004-3934.2015.06.021]
[4]位晨晨,钟明.糖尿病心肌病的发病机制[J].心血管病学进展,2020,(2):135.[doi:10.16806/j.cnki.issn.1004-3934.20.02.009]
WEI Chenchen,ZHONG Ming.Pathogenesis of Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(5):135.[doi:10.16806/j.cnki.issn.1004-3934.20.02.009]
[5]武韧 常贵全 孙凤起 李鸿珠.硫化氢对糖尿病心肌病的保护作用[J].心血管病学进展,2021,(1):52.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
WU Ren,CHANG Guiquan,SUN Fengqi,et al.Protective Effect of Hydrogen Sulfide in Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(5):52.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[6]宋元秀 崔鸣.线粒体动力学异常与相关心血管疾病[J].心血管病学进展,2021,(2):162.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
SONG Yuanxiu,CUI Ming.Correlation Between Mitochondrial Dynamics and Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2021,(5):162.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
[7]李艳鹏 马依彤.糖尿病心肌病治疗策略的研究进展[J].心血管病学进展,2022,(9):795.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.007]
LI Yanpeng,MA Yitong.Treatment Strategies for Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(5):795.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.007]
[8]曹兴丹 陈子仪 宋小刚 张玉秀 陈敏 汤吉超 李萍萍 陈永清 荆哲.EMRE在高糖环境中的变化对心肌细胞凋亡机制的研究[J].心血管病学进展,2022,(10):953.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.020]
CAO XingdanCHEN ZiyiSONG XiaogangZHANG YuxiuCHEN MinTANG JichaoLI PingpingCHEN YongqingJING Zhe.Effect of High Glucose-Induced EMRE Expressions Changes on?yocardial Apoptosis[J].Advances in Cardiovascular Diseases,2022,(5):953.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.020]
[9]林佳音 王莉莉 于小晴.胰高血糖素样肽-1受体激动剂对糖尿病心肌病的影响[J].心血管病学进展,2023,(11):1024.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.015]
LIN Jiayin,WANG Lili,YU Xiaoqing.Effect of Glucagon-Like Peptide-1 Receptor Agonist on Diabetes Cardiomyopathy[J].Advances in Cardiovascular Diseases,2023,(5):1024.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.015]
[10]王一硕 罗皓文 王晨旭 孙路轩 阿如汗 张茵 常盼.线粒体动力学在糖尿病心肌病中的研究进展[J].心血管病学进展,2023,(12):1111.[doi:10.16806/j.cnki.issn.1004-3934.2023.12.013]
WANG Yishuo LUO Haowen WANG Chenxu SUN Luxuan AruhanZHANG Yin CHANG Pan.Mitochondrial Dynamics in Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2023,(5):1111.[doi:10.16806/j.cnki.issn.1004-3934.2023.12.013]